Latest Conference Articles

February 19th 2022, 3:51pm

Genitourinary Cancers Symposium (ASCO GU)

Updated data support the common use of cabozantinib in this setting without new safety signals in patients with metastatic renal cell carcinoma.

February 18th 2022, 11:15pm

Genitourinary Cancers Symposium (ASCO GU)

Fluorodeoxyglucose PET/CT and sodium fluoride PET/CT baseline functional imaging parameters and percent change in lesion number observed on follow-up imaging was linked with overall survival and found to be prognostic in patients with metastatic genitourinary cancers.

February 18th 2022, 10:34pm

Genitourinary Cancers Symposium (ASCO GU)

Roberto Iacovelli, MD, PhD, discusses efficacy findings from the phase 2 ARIES trial in urothelial cancer.

February 18th 2022, 10:29pm

Genitourinary Cancers Symposium (ASCO GU)

Avelumab failed to demonstrate an improvement in overall survival at 1 year as frontline treatment in patients with cisplatin-ineligible, PD-L1–positive advanced urothelial cancer, though it did elicit a notable objective response rate.

February 18th 2022, 10:13pm

Genitourinary Cancers Symposium (ASCO GU)

The frontline maintenance combination of avelumab plus best supportive care continued to show an improvement in overall survival compared with BSC alone in patients with metastatic urothelial cancer who receive first-line chemotherapy.

February 18th 2022, 9:10pm

Genitourinary Cancers Symposium (ASCO GU)

The combination of lenvatinib and pembrolizumab elicited comparable antitumor activity compared with placebo plus pembrolizumab as frontline therapy in patients with advanced urothelial carcinoma who were ineligible for platinum-based chemotherapy, according to data from LEAP-011.

February 18th 2022, 7:29pm

Genitourinary Cancers Symposium (ASCO GU)

Darolutamide produced a well-tolerated safety profile in patients with metastatic castration-resistant prostate cancer, according to pooled data from long-term analyses of 3 trials.

February 18th 2022, 4:36pm

Genitourinary Cancers Symposium (ASCO GU)

The utilization of 18F-rhPSMA-7.3 imaging displayed a clinically meaningful correct detection rate.

February 18th 2022, 2:10pm

Genitourinary Cancers Symposium (ASCO GU)

The androgen receptor inhibitor darolutamide demonstrated continued efficacy and safety in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who have comorbidities or concomitant medications

February 18th 2022, 1:04am

Genitourinary Cancers Symposium (ASCO GU)

Continuous enzalutamide plus docetaxel and prednisone elicited progression-free survival improvement vs placebo with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer who had previously progressed on enzalutamide alone

February 18th 2022, 12:51am

Genitourinary Cancers Symposium (ASCO GU)

The addition of darolutamide to androgen deprivation therapy and docetaxel generated better overall survival vs placebo with ADT and docetaxel in patients with metastatic castration-sensitive prostate cancer.

February 17th 2022, 11:49pm

Genitourinary Cancers Symposium (ASCO GU)

The combination of niraparib and abiraterone acetate and prednisone led to a significant improvement in radiographic progression-free survival vs placebo plus abiraterone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.

February 17th 2022, 11:40pm

Genitourinary Cancers Symposium (ASCO GU)

Olaparib in combination with abiraterone acetate led to a 34% reduction in the risk of radiographic disease progression or death compared with placebo and abiraterone as a first-line treatment for patients with metastatic castration-resistant prostate cancer, according to results of the phase 3 PROpel trial.

February 17th 2022, 10:49pm

Genitourinary Cancers Symposium (ASCO GU)

A greater portion of patients with metastatic castration-sensitive prostate cancer achieved an early and deep prostate-specific antigen reduction from baseline of 90% or more when treated with apalutamide compared with enzalutamide.

February 10th 2022, 5:00pm

PER® Winter Lung Cancer Conference

With 9 approved markers in non–small cell lung cancer and a plethora of established and emerging therapies that have been designed to target them, the need for molecular testing is more important than ever.

February 9th 2022, 12:16am

PER® Winter Lung Cancer Conference

Lyudmila A. Bazhenova, MD, discusses future research questions with fam-trastuzumab deruxtecan-nxki in HER2-mutated lung cancer.

February 8th 2022, 10:52pm

PER® Winter Lung Cancer Conference

Upal Basu Roy, PhD, MPH, discusses the challenges of interpreting molecular testing results in lung cancer.

February 8th 2022, 9:38pm

PER® Winter Lung Cancer Conference

Lyudmila Bazhenova, MD, explores key challenges faced with diagnosing and appropriately treating patients with non–small cell lung cancer that harbors EGFR exon 20 insertion mutations and provides insight into the second-line options that have recently garnered regulatory approval.

February 8th 2022, 7:05pm

PER® Winter Lung Cancer Conference

Checkpoint inhibitors are often used in the advanced stage, but Erin A. Gillaspie, MD, MPH, argues that the data show physicians should consider utilizing this class of agents earlier in treatment.

February 7th 2022, 10:50pm

PER® Winter Lung Cancer Conference

Russell Kenneth Hales, MD, discusses the role of multidisciplinary care in locally advanced lung cancer.